2004
DOI: 10.1002/cncr.20381
|View full text |Cite
|
Sign up to set email alerts
|

Novel therapies for myelodysplastic syndromes

Abstract: BACKGROUND.The assessment of patients with myelodysplastic syndromes (MDS) and the choice of therapies remain challenging. New therapies are now emerging after the identification of molecular targets that result in improvement of hematologic parameters and may hold promise for the prevention of disease progression. METHODS.A review of the English literature was performed that included original articles and related reviews from MEDLINE (PubMed) and abstracts based on published meeting material. RESULTS.MDS i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
26
0
2

Year Published

2006
2006
2008
2008

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 47 publications
(28 citation statements)
references
References 111 publications
0
26
0
2
Order By: Relevance
“…Because Thal and especially lenalidomide have been reported to exhibit clinical activity in patients diagnosed with myelodysplastic syndrome (MDS), 19,20 we examined whether there were differences in the development of MDS-associated cytogenetic abnormalities (MDS-CA) between the 2 study arms. 21 The 5-year cumulative frequency of MDS-CA was identical at 4% in both arms, indicating that Thal provided no protective effect against the development of therapy-related myelodysplastic syndrome (t-MDS).…”
Section: Implications Of Randomization To Thalidomide On Mri-defined mentioning
confidence: 99%
“…Because Thal and especially lenalidomide have been reported to exhibit clinical activity in patients diagnosed with myelodysplastic syndrome (MDS), 19,20 we examined whether there were differences in the development of MDS-associated cytogenetic abnormalities (MDS-CA) between the 2 study arms. 21 The 5-year cumulative frequency of MDS-CA was identical at 4% in both arms, indicating that Thal provided no protective effect against the development of therapy-related myelodysplastic syndrome (t-MDS).…”
Section: Implications Of Randomization To Thalidomide On Mri-defined mentioning
confidence: 99%
“…[1][2][3][4] Older patients, which constitute the large majority, generally receive supportive care only, low-dose chemotherapy or investigational agents. The United States Food and Drug Administration (FDA) recently approved 5-azacytidine (Vidaza, Pharmion, Boulder, CO), lenalidomide (Revlimid, Celgene, Summit, NJ), and decitabine (Dacogen, MGI Pharma, Bloomington, MN; SuperGen, Dublin, CA; Johnson & Johnson Pharmaceutical Research and Development LLC, Raritan, NJ) as new therapeutic options for patients with MDS, but treatments with improved safety, especially those that target new disease-related growth pathways, are needed to improve patient outcomes.…”
Section: Introductionmentioning
confidence: 99%
“…1,2 Several prognostic models, including the International Prognostic Scoring System (IPSS), have been proposed to account for the heterogeneity in MDS. [3][4][5] Prognostic factors include the percent of bone marrow blasts, cytogenetic abnormalities, the degree and number of cytopenias (according to the IPSS), and others.…”
mentioning
confidence: 99%